Medical technology firm Orchestra BioMed listed on Nasdaq after finalizing SPAC merger


Orchestra BioMed's products in development include a potential treatment for high blood pressure in patients with pacemakers.

Previous CEO of Emerson Health to chair state's hospital industry group
Next Nationwide Children's AI spinoff acquired by $200M startup connecting patients with clinical trials